Нефрология / Под общ. ред. И.Е. Тареевой - М.: Медицина, 2000. - 688 с.
Booth A., Harper L., Hammad T. et al. Prospective study of TNF alpha blocade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis // J. Am. Soc. Nephrol. - 2004. - Vol. 15. - P. 717-721.
Booth A., Pusey C., Jayne D. Renal vasculitis - an update in 2004 // Nephrol. Dial. Transplant. - 2004. - Vol. 19. - P. 1964-1968.
D’Agati V. Antineutrophil cytoplasmic autoantibody and vasculitis: much more than a disease marker // J. Clin. Invest. - 2002. - Vol. 110. - P. 919-921.
Eisenberger U., Fakhouri F., Vanhille Ph. et al. ANCA- negative pauci- immune renal vasculitis: histology and outcome // Nephrol. Dial. Transplant. - 2005. - Vol. 20. - P. 1392-1399.
Falk R., Jennette J. Thoughts about the classification of small vessel vasculitis // J. Nephrol. - 2004. - Vol. 17. - P. 3-9.
-ascin G., Jayne D., Group E. Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis // J. Am. Soc. Nephrol. - 2002.
Harper L., Cockwell P., Adu D., Savage C. Neutrophil priming and apoptosis in anti- neutrophil cytoplasmic autoantibody-associated vasculitis // Kidney Int. - 2001. - Vol. 59. - P. 1729-1738.
Hellmich B., Csernok E., Gross W.L. 20 years with ANCA: from seromarker to a major pathogenic player in vasculitis // J. Leukoc. Biol. - 2003. - Vol. 74. - P. 1-2.
Keogh K., Ytterberg S., Fervenza F. et al. Rituximab for refractery Wegener’s granulomatosis: Report of a prospective, open-label pilot trial // Am. J. Respir. Crit. Care Med. - 2006. - Vol. 173. - P. 180-187.
Lane S., Watts R., Shepstone L., Scott D. Primary systemic vasculitis: clinical features and mortality // QJM. - 2005. - N 2. - P. 97-111.